Condition: Primary Immunodeficiency Diseases (PID) · Sponsor: Takeda
This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This survey will conduct in use of medical database called PIDJ2.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Study Director
Always discuss trial participation with your own doctor first.
| Takeda selected site | Tokyo, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06565078